Daiichi Sankyo: Anemia, Iron-Deficiency trials

The registry lists 20 Anemia, Iron-Deficiency studies with Daiichi Sankyo as lead sponsor. 0 are open to participants now and 17 have results posted.

Phase 2 5Phase 3 11Phase 4 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044CompletedNCT04269707Phase 3Results posted
• Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDACompletedNCT03523117Phase 3Results posted
• Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-StudyCompletedNCT03037931Phase 3Results posted
• Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency AnemiaTerminatedNCT02826681Phase 2Results posted
• A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDACompletedNCT02410213Phase 2Results posted
• Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric BypassCompletedNCT02086968Phase 4Results posted
• Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV IronCompletedNCT01950247Phase 4Results posted
• Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine BleedingCompletedNCT01307007Phase 2Results posted
• Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in WomenCompletedNCT01290315Phase 2Results posted
• Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)CompletedNCT00982007Phase 3Results posted
• Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal FunctionCompletedNCT00981045Phase 3Results posted
• Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency AnemiaCompletedNCT00740246Phase 3Results posted
• Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency AnemiaCompletedNCT00704353Phase 3Results posted
• Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency AnemiaCompletedNCT00704028Phase 3Results posted
• Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency AnemiaCompletedNCT00703937Phase 3Results posted
• Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum PatientsCompletedNCT00548860Phase 3Results posted
• Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease PatientsCompletedNCT00548691Phase 3Results posted
• Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency AnemiaWithdrawnNCT04968379Phase 2
• Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency AnemiaCompletedNCT01984554
• Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)WithdrawnNCT01151592Phase 4